

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-35. (canceled)

36. (currently amended) A process for preparing a monoclonal antibody directed against endothelial cells with an angiogenic phenotype ~~according to claim 34~~ that is capable of inhibiting angiogenesis,

said antibody having the following characteristics:

said antibody binds to a surface of the endothelial cells with an angiogenic phenotype, and

said antibody recognizes a unit present exclusively on the endothelial cells with an angiogenic phenotype,

said endothelial cells with an angiogenic phenotype having the following properties:

said endothelial cells form tubes in presence of growth factor VEGF in a collagen gel,

said endothelial cells proliferate under action of VEGF,

said endothelial cells are protected from apoptosis by VEGF,

and

said endothelial cells expression of VEGFR-2 is increased 4-fold in comparison with cells with a non-angiogenic phenotype,

comprising the steps of:

immunizing an animal by injection of said endothelial  
cells with an angiogenic phenotype;

fusing myelomas of an animal and splenocytes of an  
animal in order to obtain hybridomas;

preparing a culture of said hybridomas;

cloning of said hybridomas and secreting antibodies  
against cells with an angiogenic phenotype; and

verifying that said antibodies inhibit said properties  
of said cells with an angiogenic phenotype ~~angiogenesis-~~  
~~inhibiting properties of said antibodies vis-à-vis angiogenic~~  
cells.

37-48. (canceled)